UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of
1934
Date of
Report (Date of Earliest Event Reported): February 15,
2017
MetaStat, Inc.
(Exact
name of registrant as specified in its charter)
Nevada
(State
or other jurisdiction of incorporation)
|
000-52735
|
20-8753132
|
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
27 Drydock Ave., 2nd Floor
Boston,
Massachusetts 02210
(Address of
principal executive offices and zip code)
(617)
531-6500
(Registrant's
telephone number including area code)
(Registrant's
former name or former address, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of registrant under
any of the following provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12(b) under the Exchange
Act (17 CFR 240.14a-12(b))
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
In June
2015, MetaStat, Inc. (the “Company”) entered into a
consulting agreement (the “Agreement”) with Dr.
Oscar Bronsther, the Company’s former chief executive officer
and a current member of its board of directors, pursuant to which
the Company agreed, among other things, to make certain cash
payments to Dr. Bronsther. On February 15, 2017, in order to
satisfy an outstanding cash obligation to Dr. Bronsther in the
approximate amount of $160,000, the Company and Dr. Bronsther
agreed that the Company will (1) pay to Dr. Bronsther an aggregate
amount of $66,000 and (2) issue to Dr. Bronsther a five-year
warrant to purchase 75,618 shares of the Company’s common
stock at an exercise price of $3.00 per share (the
“Warrant”).
Item 3.02. Unregistered Sales of Equity
Securities.
As
described more fully in Item 8.01 above, on February 15, 2017,
the Company issued the Warrant. The issuance was exempt from
registration pursuant to Section 4(2) of, and Regulation D
promulgated under, the Securities Act of 1933, as
amended.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
|
METASTAT,
INC.
|
|
|
|
|
|
|
|
By: |
/s/
Douglas A. Hamilton
|
|
Dated: February 16,
2017
|
|
Name:
Douglas A. Hamilton
Title: President
and CEO
|